Breast Cancer News
65.9K views | +2 today
 
Scooped by Susan Zager
onto Breast Cancer News
Scoop.it!

Celldex Therapeutics Initiates METRIC, an Accelerated Approval Study of Glembatumumab Vedotin in Patients with Triple Negative Breast Cancer

Celldex Therapeutics Initiates METRIC, an Accelerated Approval Study of Glembatumumab Vedotin in Patients with Triple Negative Breast Cancer | Breast Cancer News | Scoop.it

"HAMPTON, N.J., Dec 02, 2013 (GLOBE NEWSWIRE via COMTEX) -- Celldex Therapeutics, Inc. CLDX -2.09% today announced that it has launched a randomized study (METRIC) of Glembatumumab vedotin (CDX-011) in patients with metastatic triple negative breast cancers that over-express glycoprotein NMB (gpNMB). Glembatumumab vedotin is an antibody-drug conjugate that targets and binds to gpNMB, a specific protein that is expressed in breast cancer which promotes the migration, invasion and metastasis of the disease. It is also highly expressed in triple negative breast cancers where it is associated with increased risk of recurrence. Initial sites are now open to screen patients in the United States. Additional sites in the United States and in Canada and Australia will open in early 2014. The study is expected to include up to 100 sites and will enroll approximately 300 patients.

"In the Phase 2 EMERGE study, Glembatumumab vedotin elicited impressive response rates that correlated with a survival benefit for patients with metastatic breast cancer that also had high levels of gpNMB on the surface of their tumor cells," said Thomas Davis, M.D., Senior Vice President and Chief Medical Officer of Celldex. "Currently, patients with triple negative breast cancer have very limited treatment options and no targeted interventions. We believe gpNMB could be an important marker in breast cancer and that Glembatumumab vedotin holds significant potential as a possible targeted therapy for women facing this disease."                                           

Susan Zager's insight:

For more information go to: http://www.celldex.com/pipeline/cdx-011.php


more...
Maria Fowler's curator insight, December 2, 2013 9:18 PM

Trials are a good thing. This one targets potential TNBC tumors.

Breast Cancer News
Latest News, Research,  Articles of Interest, and Blog Posts
Curated by Susan Zager
Your new post is loading...
Scooped by Susan Zager
Scoop.it!

Compassion & Choices | Medical Aid in Dying Act Wins Swift Assembly Committee Vote

Compassion & Choices | Medical Aid in Dying Act Wins Swift Assembly Committee Vote | Breast Cancer News | Scoop.it
Susan Zager's insight:
Hopefully many more states will follow along.
more...
No comment yet.
Scooped by Susan Zager
Scoop.it!

Antibody appears to attack cancer cells, leaving other cells unscathed

Antibody appears to attack cancer cells, leaving other cells unscathed | Breast Cancer News | Scoop.it

"An antibody has been developed from the body's own immune system that preferentially attacks cancer cells. The antibody works by targeting a natural defense mechanism that cancer tumors exploit. Cells in the body essentially use a home security system that relies on certain proteins to protect the cell surface and keep it safe. These proteins help the cell avoid injury and even death from unwanted activation of the immune system."

Susan Zager's insight:

To see the study go to: http://www.cell.com/cell-reports/fulltext/S2211-1247(16)30465-X

 

more...
No comment yet.
Scooped by Susan Zager
Scoop.it!

Pembrolizumab Promising in Metastatic Triple-Negative Breast Cancer | Cancer Network

Pembrolizumab Promising in Metastatic Triple-Negative Breast Cancer | Cancer Network | Breast Cancer News | Scoop.it
The KEYNOTE-012 trial shows that pembrolizumab has activity and acceptable toxicity as single-agent therapy in advanced triple-negative breast cancer.
Susan Zager's insight:

To see the original study go to: http://jco.ascopubs.org/content/early/2016/04/27/JCO.2015.64.8931.abstract

more...
No comment yet.
Scooped by Susan Zager
Scoop.it!

You Pay to Read Research You Fund. That’s Ludicrous

You Pay to Read Research You Fund. That’s Ludicrous | Breast Cancer News | Scoop.it
Saying that Sci-Hub is about copyright infringement is like saying the Boston Tea Party was about late-night vandalism.
more...
No comment yet.
Scooped by Susan Zager
Scoop.it!

What I Said to the Largest Convening of Cancer Researchers in the Country Yesterday:

What I Said to the Largest Convening of Cancer Researchers in the Country Yesterday: | Breast Cancer News | Scoop.it
Thank you. Thank you very, very much. You’re extremely gracious and generous.
Susan Zager's insight:

Here's a link to @VP Biden speaking about the #moonshot #cancer program. It's very important to stay involved as he spells out the key points in this speech. We must make sure treatment and reserach for Stage IV is part of the molding of this project. This approach can lead to a help real cure for all stages and end deaths from this horrible disease.

This program is for all parties to be involved- so this is not a political statement.

more...
No comment yet.
Scooped by Susan Zager
Scoop.it!

Moffitt Cancer Center Researchers Discover Liver Metastases have Different Radiation Sensitivities Based on Primary Tumor Histology

Moffitt Cancer Center Researchers Discover Liver Metastases have Different Radiation Sensitivities Based on Primary Tumor Histology | Breast Cancer News | Scoop.it

"Radiation is a commonly used therapeutic option to treat liver metastases, with the majority of tumors maintained under control after one year. However, some patients do not respond as well to radiation treatment, and the factors that predict patient outcomes are unclear. Moffitt Cancer Center researchers report that liver metastases have different sensitivities to radiation therapy based on the location of the primary tumor. 

Previously, Moffitt researchers developed a radiosensitivity index (RSI) that predicts how well tumors respond to radiation therapy based on the expression of 10 different genes. 

“The radiosensitivity index is the most studied and validated radiation specific signature currently available,” said Javier Torres-Roca, M.D., associate member and director of research in Moffitt’s Department of Radiation Oncology. “It is an important step towards gaining a better understanding of radiation sensitivity and developing a personalized approach to radiation treatment.” 

Susan Zager's insight:

To see the original study go to: http://www.redjournal.org/article/S0360-3016%2816%2930040-2/abstract

 

more...
No comment yet.
Scooped by Susan Zager
Scoop.it!

"State of Cancer Care in America: 2016" Report Finds Unprecedented Opportunity Amid Profound Turbulence

"State of Cancer Care in America: 2016" Report Finds Unprecedented Opportunity Amid Profound Turbulence | Breast Cancer News | Scoop.it
This year’s report clearly shows that strengthening the delivery system for cancer care has to be pursued just as aggressively as its research agenda.
Susan Zager's insight:

There are many problems with the State of Cancer in the USA. This article explains a lot of the report. To see the full report go to: http://jop.ascopubs.org/content/early/2016/03/17/JOP.2015.010462.full.pdf+html

more...
No comment yet.
Scooped by Susan Zager
Scoop.it!

Will Changes in Medicare Part B Drug Prescribing Cut Costs?

Will Changes in Medicare Part B Drug Prescribing Cut Costs? | Breast Cancer News | Scoop.it
CMS announced last week that new healthcare payment models would be utilized in Medicare Part B drug prescribing practices.
more...
No comment yet.
Scooped by Susan Zager
Scoop.it!

Terminally ill campaigner fighting for right to work

Terminally ill campaigner fighting for right to work | Breast Cancer News | Scoop.it
Jacci Woodcock was forced out of her job after being diagnosed with breast cancer and is fighting to change the law
Susan Zager's insight:
This is unacceptable and unfortunately happens in other countries besides the UK. Terminally ill patients including cancer patients who are able to work should not be discriminated against.
more...
No comment yet.
Scooped by Susan Zager
Scoop.it!

Bankruptcy: The Other Cost of Cancer

Bankruptcy: The Other Cost of Cancer | Breast Cancer News | Scoop.it
The high cost of cancer can include financial stress. What happens to people who declare bankruptcy? Should physicians discuss costs of cancer treatment?
more...
No comment yet.
Scooped by Susan Zager
Scoop.it!

The mental trauma of severe disease - LMU Munich

The mental trauma of severe disease - LMU Munich | Breast Cancer News | Scoop.it

The majority of women suffering from breast cancer develop symptoms of post-traumatic stress in the months following receipt of the diagnosis. The latest results of the Cognicares study, led by Dr. Kerstin Hermelink of the Breast Cancer Center in the Department of Gynecology and Obstetrics at the LMU Medical Center, show that such symptoms can still be detected a year after patients have been informed of their condition. The new findings appear in the journal Psycho-Oncology.

Susan Zager's insight:

Many of us have talked about PTSD and Breast Cancer. Check out the original study at: http://onlinelibrary.wiley.com/doi/10.1002/pon.4102/abstract

 

more...
No comment yet.
Scooped by Susan Zager
Scoop.it!

Adjuvant Denosunab To prevent Fractures and Breast Cancer Recurrence

Adjuvant Denosunab To prevent Fractures and Breast Cancer Recurrence | Breast Cancer News | Scoop.it

The ABCSG-18 trial demonstrates that every breast cancer patient being offered adjuvant aromatase inhibitor (AI) therapy should be offered denosumab as well. There are 2 issues involved, either of which would mandate a discussion of using denosumab: One is prevention of fractures not related to cancer, and the other is the prevention of breast cancer relapse.

ABCSG-18 is a large prospective, double-blind, placebo-controlled trial involving 3,420 women, mostly in Austria. Characteristics of the study participants are listed in Table 1. Women receiving adjuvant non-steroidal AI daily for 5 years were assigned to receive either placebo or 60 mg of subcutaneous denosumab (Prolia, Amgen) every 6 months. Median follow-up for the fracture analysis was 38 months, and for the disease-free survival (DFS) analysis presented at SABCS in December 2015, about 45 months.

Susan Zager's insight:

This study looks at using denosumab for prevention of fractures not related to cancer, and  prevention of breast cancer relapse.

more...
No comment yet.
Scooped by Susan Zager
Scoop.it!

Study: $3B will be wasted on unused portion of cancer drugs

Study: $3B will be wasted on unused portion of cancer drugs | Breast Cancer News | Scoop.it
TRENTON, N.J. (AP) — High prices for cancer medicines aren't the only reason they cost insurers and patients so much.Waste pads the bill, a study finds, because infused cancer drugs are distributed in the U.S. in vials that usually contain more...
more...
No comment yet.
Scooped by Susan Zager
Scoop.it!

Pictilisib for Estrogen Receptor–Positive, Aromatase Inhibitor–Resistant, Advanced or Metastatic Breast Cancer

Pictilisib for Estrogen Receptor–Positive, Aromatase Inhibitor–Resistant, Advanced or Metastatic Breast Cancer | Breast Cancer News | Scoop.it
Pictilisib for Estrogen Receptor–Positive, Aromatase Inhibitor–Resistant, Advanced or Metastatic Breast Cancer
Susan Zager's insight:

You made need to sign in for the article, but it's worth it. To see the original study go to: http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)00106-6/abstract?cc=y=

more...
No comment yet.
Scooped by Susan Zager
Scoop.it!

Prospects in the Management of Breast Cancer

Prospects in the Management of Breast Cancer | Breast Cancer News | Scoop.it
The panelists, Adam M. Brufsky, MD; Sara A. Hurvitz, MD; Joyce A. O’Shaughnessy, MD; Hope S. Rugo, MD; and Christy A. Russell, MD, share final thoughts on future improvements in the management of breast cancer.
Susan Zager's insight:

Interesting panel discussion including Triple Negative Breast Cancer and MBC

more...
No comment yet.
Scooped by Susan Zager
Scoop.it!

Beating Cancer: The Real Life Battle for Patients and Their Loved Ones

Beating Cancer: The Real Life Battle for Patients and Their Loved Ones | Breast Cancer News | Scoop.it
Community,news,cure,cure today, cure magazine
Susan Zager's insight:
It's time the real facts of Metastatic breast cancer come out. Great article!
more...
No comment yet.
Scooped by Susan Zager
Scoop.it!

New strides in metastatic breast cancer research give patients hope

New strides in metastatic breast cancer research give patients hope | Breast Cancer News | Scoop.it
Metastatic breast cancer kills around 40,000 women (and men) a year, but a handful of MBC patients who visited Fred Hutch recently say they're more encouraged than ever. Find out why.
Susan Zager's insight:

Check out this great article and Beth Caldwell's input. It also speaks about the #MBCProject

more...
No comment yet.
Scooped by Susan Zager
Scoop.it!

ANGLE device able to track spread of breast cancer

ANGLE device able to track spread of breast cancer | Breast Cancer News | Scoop.it

"The American Association for Cancer Research annual meeting will be told Partsortix performed well in a head-to-head trial with the current method of assessing for cancer spread – painful and invasive surgery to cut out a sliver of affected tissue.

Metastasis is responsible for the vast majority of breast cancer deaths and treatment tends to be based on the biology of the initial tumour biology; however, it is known the cancer changes characteristics as it seeds around the body, so guidelines now state that sample tissue is taken from an area where the cancer has spread, so the drug regimen can be altered.

Susan Zager's insight:

Looking forward to more information coming out of @AACR16

more...
No comment yet.
Scooped by Susan Zager
Scoop.it!

#Cancer: Researchers Are Conducting Huge Studies Using Twitter, Facebook

#Cancer: Researchers Are Conducting Huge Studies Using Twitter, Facebook | Breast Cancer News | Scoop.it

"Nearly 40% of men and women will be diagnosed with cancer in their lifetimes, with about 1.7 million of those cases expected in 2016 in the United States (according to the National Cancer Institute). These patients are hoping for better treatments and, hopefully someday, cures. They could also be valuable resources, helping experts develop better therapies, if only staff at research centers like Dana-Farber Cancer Institute in Boston could study their unique cases. Even patients with the same diagnosis, such as breast cancer, have different genetic makeups, both in their healthy cells and in their tumors. These differences provide clues to new genetic factors that may cause the disease, why some patients respond especially well to certain treatments, why some tumors are so resistant to treatment, and how people of different ages or ethnicities are affected.

There's a large community of people, but they are spread out. So Broad Institute/Dana-Farber Integrative Cancer Biology Program in Cambridge, Massachusetts, formed the Metastatic Breast Cancer Project to find a long tail solution: Find people on the Internet. "The traditional way is that when a patient is at [a research] institution, someone will approach them and ask them in person," says Wagle. "We're trying to complement that by doing this 21st century, go directly to patients." That strategy has already netted about 1,700 people (both women and men) with metastatic breast cancer—cancer that has spread beyond the breast, threatening other parts of the body. Wagle says that 95% of them have provided some information about their condition, and that more than 900 have agreed to share medical records, tumor samples, and saliva (for genetic sequencing)."

Susan Zager's insight:

Great article about the incredible work being done at the Broad Institute/Dana Farber Integrative Cancer Biology Project formed to conduct groudbreaking research of Metastatic Breast Cancer by going directly to patients.To learn more go to their web site at:  https://www.mbcproject.org/

more...
No comment yet.
Scooped by Susan Zager
Scoop.it!

U.S. CANCER CARE SYSTEM
ILL-EQUIPPED TO DELIVER
NEW ADVANCES TO PATIENTS

U.S. CANCER CARE SYSTEM<br/>ILL-EQUIPPED TO DELIVER<br/>NEW ADVANCES TO PATIENTS | Breast Cancer News | Scoop.it
Susan Zager's insight:

Disturbing cancer care evalutated by @ASCO.

more...
No comment yet.
Scooped by Susan Zager
Scoop.it!

Ten Huge Drug Rip-Offs—And Big Pharma's Infuriating Campaign to Keep on Price-Gouging

Ten Huge Drug Rip-Offs—And Big Pharma's Infuriating Campaign to Keep on Price-Gouging | Breast Cancer News | Scoop.it
When did you become aware of the obscene prices the pharmaceutical industry is charging for drugs? For many it was when a smirking Martin Shkreli, founder of Turing Pharmaceuticals, testified on the Hill in February about his price hike of the antiparasitic drug Daraprim from $13.50 to $750, after w
Susan Zager's insight:

Great article by Martha Rosenberg, exposing pharmaceutical companies gouging prices for drugs.

more...
No comment yet.
Scooped by Susan Zager
Scoop.it!

Woman's breast cancer warning sign photo goes viral

Woman's breast cancer warning sign photo goes viral | Breast Cancer News | Scoop.it
A woman's very personal photo of an unusual sign of breast cancer went viral and she hopes many more get the important message.
Susan Zager's insight:

An ultrasound determined Armstrong's tumor was located far inside her breast, close to her pectoral muscle. Her posted photo shows that breast doesn't always look the same. 

"The reality is breast cancer can present in some very unusual ways," Dr. Deanna Attai, the president of the American Society of Breast Surgeons, said.

more...
No comment yet.
Scooped by Susan Zager
Scoop.it!

My Turn: Biosimilar drugs are intriguing, but we need full disclosure

My Turn: Biosimilar drugs are intriguing, but we need full disclosure | Breast Cancer News | Scoop.it
Biosimilar drugs can lower costs for patients - but doctors need to know when they've been administered. That's where Arizona lawmakers come in.
more...
No comment yet.
Scooped by Susan Zager
Scoop.it!

Men with breast cancer being failed as they are 'treated like women'

Men with breast cancer being failed as they are 'treated like women' | Breast Cancer News | Scoop.it

First major investigation into male breast cancer reveals significant
differences in biology of disease, despite same treatments for men and women.

"Men with breast cancer are being failed because they are being “treated like women”, experts have warned. 

Breast cancer is usually thought of as a woman’s disease – but nearly 400 men receive a diagnosis in the UK each year. 

Until now, doctors have assumed that the biology of the disease is the same, and that the same treatments should be meted out. But the first major investigation into male breast cancer has revealed significant differences.""

Susan Zager's insight:

The article looks at men from nine countries with breast cancer and expose that they are being failed because they are being “treated like women”, experts have warned. 

more...
No comment yet.
Scooped by Susan Zager
Scoop.it!

Cynvenio Honors Triple Negative Breast Cancer Day with Clinical Trial 

Cynvenio Honors Triple Negative Breast Cancer Day with Clinical Trial  | Breast Cancer News | Scoop.it

"Cynvenio Biosystems, Inc., a diagnostics company dedicated to enabling the new era of individualized medicine for all cancer patients, today will honor Triple Negative Breast Cancer Day by launching a clinical trial for women with triple negative breast cancer (TNBC) using the company’s non-invasive liquid biopsy technology to monitor participants and identify early signs of metastasis. An event for breast cancer advocates, including women with the disease and those enrolling in the trial, will take place this morning in Beverly Hills at the Pink Lotus Breast Center - the first site to participate in the nationwide study."

Susan Zager's insight:

This is a trial that uses a "liquid biopsy" to predict early signs of metastasis.especially for the hard to predict and deadly Triple Negative Breast Cancer (TNBC).  For more information about TNBC go to: http://www.tnbcfoundation.org. For more information about the trial go to: https://clinicaltrials.gov/show/NCT02639832

 

more...
No comment yet.